

A Clinical Guide to Inherited Metabolic Diseases

This user-friendly clinical handbook provides a clear and concise overview of how to go about recognizing and diagnosing inherited metabolic diseases. The reader is led through the diagnostic process from the identification of those features of an illness suggesting that it might be metabolic through the selection of appropriate laboratory investigation to a final diagnosis.

The book is organized into chapters according to the most prominent presenting problem of patients with inherited metabolic diseases: neurologic, hepatic, cardiac, metabolic acidosis, dysmorphism, and acute catastrophic illness in the newborn. It also includes chapters on general principles, laboratory investigation, neonatal screening, and the principles of treatment.

This new edition includes much greater depth on mitochondrial disease and congenital disorders of glycosylation. The chapters on neurological syndrome and newborn screening are greatly expanded, as are those on laboratory investigation and treatment, to take account of the very latest technological developments.

Dr J. T. R. Clarke is Professor of Paediatrics at the University of Toronto and a Senior Associate Scientist in the Research Institute of the Hospital for Sick Children, as well as continuing Head of the Genetic Metabolic Diseases Program of the Hospital. He is a Fellow of the Royal College of Physicians of Canada and the Canadian College of Medical Geneticists. He has won awards for postgraduate paediatric teaching and for excellence in paediatric medical care. He is consulted extensively by government and industry on matters relating to the management of inherited metabolic diseases and newborn screening. He is internationally respected for his expertise in the general area of metabolic genetics and is widely sought as a speaker and educator in this field. He has given over 100 invited lectures on inherited metabolic diseases in countries around the globe.

Cambridge University Press
0521614996 - A Clinical Guide to Inherited Metabolic Diseases, Third Edition
Joe T. R. Clarke
Frontmatter
[More information](#)

A Clinical Guide to Inherited Metabolic Diseases

Third Edition

Joe T. R. Clarke, MD, PhD, FRCPC

Division of Clinical & Metabolic Genetics, Hospital for Sick Children,
555 University Avenue, Toronto, Ontario M5G 1X8 CANADA



Cambridge University Press
0521614996 - A Clinical Guide to Inherited Metabolic Diseases, Third Edition
Joe T. R. Clarke
Frontmatter
[More information](#)

CAMBRIDGE UNIVERSITY PRESS
Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo

Cambridge University Press
The Edinburgh Building, Cambridge CB2 2RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org
Information on this title: www.cambridge.org/9780521614993

© Joe T. R. Clarke 2005

This publication is in copyright. Subject to statutory exception
and to the provisions of relevant collective licensing agreements,
no reproduction of any part may take place without
the written permission of Cambridge University Press.

First published 1996
Second edition 2002
Third edition 2005

Printed in the United Kingdom at the University Press, Cambridge

A catalogue record for this publication is available from the British Library

ISBN-13 978-0-521-61499-3 paperback
ISBN-10 0-521-61499-6 paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or
third-party internet websites referred to in this publication, and does not guarantee that any content on
such websites is, or will remain, accurate or appropriate.

Contents

	<i>Reviews of first edition</i>	<i>page</i> x
	<i>Reviews of second edition</i>	xi
	<i>List of tables</i>	xii
	<i>List of figures</i>	xvi
	<i>Preface</i>	xix
1	General principles	1
	Introduction	1
	Some general metabolic concepts	2
	Disease results from point defects in metabolism	4
	Accumulation of substrate	4
	Accumulation of a normally minor metabolite	6
	Deficiency of product	7
	Secondary metabolic phenomena	9
	Inborn errors of metabolism are inherited	9
	Autosomal recessive disorders	9
	X-linked recessive disorders	11
	Autosomal dominant disorders	13
	Mitochondrial inheritance	14
	Inherited metabolic diseases may present at any age	16
	Three sources of diagnostic confusion	17
	Confusion with common acquired conditions	17
	Confusion caused by association with	
	intercurrent illness	20
	Confusion arising from genetic heterogeneity	21
	Congenital malformations and inborn errors of metabolism	21
	The internet is particularly important	21
	Suggested reading	27
2	Neurologic syndrome	28
	Chronic encephalopathy – without non-neural involvement	29
	Gray matter disease (polidystrophy)	29
	Psychomotor retardation or dementia	29
	Seizures	34
	White matter disease (leukodystrophy)	47

vi	Contents	
	Chronic encephalopathy – with non-neural tissue involvement	50
	Acute encephalopathy	53
	Hyperammonemia	55
	Leucine encephalopathy (maple syrup urine disease – MSUD)	61
	Reye-like acute encephalopathy (fatty acid oxidation defects)	61
	Acute encephalopathy with metabolic acidosis	63
	Hypoglycemia	63
	Stroke	63
	Movement disorder	63
	Ataxia	63
	Choreoathetosis and dystonia	69
	Parkinsonism	71
	Myopathy	72
	Acute intermittent muscle weakness	72
	Progressive muscle weakness	73
	Myoglobinuria (myophosphorylase deficiency phenotype)	74
	Myoglobinuria (CPT II deficiency phenotype)	77
	Myopathy as a manifestation of multisystem disease (mitochondrial myopathies)	77
	Autonomic dysfunction	79
	Psychiatric problems	79
	Suggested reading	87
3	Metabolic acidosis	90
	Buffers, ventilation, and the kidney	90
	Is the metabolic acidosis the result of abnormal losses of bicarbonate or accumulation of acid?	92
	Metabolic acidosis caused by abnormal bicarbonate losses	92
	Metabolic acidosis resulting from accumulation of organic anion	94
	Lactic acidosis	94
	Pyruvate accumulation	95
	PDH deficiency	98
	PC deficiency	99
	Multiple carboxylase deficiency	99
	NADH accumulation	100
	Ketoacidosis	101
	Mitochondrial acetoacetyl-CoA thiolase deficiency (β-ketothiolase deficiency)	102
	Succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency	103
	Organic aciduria	104
	Methylmalonic acidemia (MMA)	104
	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency	110
	Glutaric aciduria	110
	Dicarboxylic aciduria	112
	Ethylmalonic aciduria	113
	D-Lactic acidosis	113

vii	Contents	
	Adventitious organic aciduria	114
	Suggested reading	115
4	Hepatic syndrome	116
	Jaundice	116
	Unconjugated hyperbilirubinemia	116
	Conjugated hyperbilirubinemia	118
	Hepatomegaly	118
	Hypoglycemia	120
	Ways to increase glucose production	120
	Ways to decrease peripheral glucose utilization	122
	An approach to the differential diagnosis of hypoglycemia	125
	Hepatocellular dysfunction	133
	Investigation	139
	Liver function tests	139
	Fasting tests	139
	Suggested reading	141
5	Cardiac syndromes	143
	Cardiomyopathy	143
	Initial investigation of possible inherited metabolic cardiomyopathy	148
	Glycogen storage disease, type II (GSD II or Pompe disease)	149
	Primary systemic carnitine deficiency	151
	Fabry disease	151
	Mitochondrial cardiomyopathies	152
	Arrhythmias	153
	Coronary artery disease	155
	Familial hypercholesterolemia	155
	Suggested reading	159
6	Storage syndrome and dysmorphism	162
	General characteristics of the dysmorphism resulting from inborn errors of metabolism	162
	What are the types of inherited metabolic diseases in which dysmorphism might be expected to be prominent?	164
	Lysosomal disorders	165
	Peroxisomal disorders	178
	Mitochondrial disorders	182
	Biosynthetic defects	183
	What sort of metabolic studies are most likely to be diagnostically productive in the investigation of dysmorphism?	195
	Suggested reading	196
7	Acute metabolic illness in the newborn	198
	Suspicion	198
	Initial laboratory investigation	200
	Five clinical ‘syndromes’	202

viii Contents

	Encephalopathy without metabolic acidosis	203
	Maple syrup urine disease (MSUD)	203
	Urea cycle enzyme defects (UCED)	205
	Nonketotic hyperglycinemia (NKHG)	208
	Pyridoxine-dependent seizures	209
	Peroxisomal disorders (Zellweger syndrome)	209
	Molybdenum cofactor deficiency (sulfite oxidase/xanthine oxidase deficiency)	209
	Encephalopathy with metabolic acidosis	210
	Organic acidurias	210
	Congenital lactic acidosis	213
	Dicarboxylic aciduria	214
	Neonatal hepatic syndrome	215
	Jaundice	215
	Severe hepatocellular dysfunction	217
	Hypoglycemia	220
	Cardiac syndrome	222
	Intractable cardiac arrhythmias	222
	Cardiomyopathy	222
	Nonimmune fetal hydrops	223
	Initial management	223
	Summary comments	226
	Suggested reading	226
8	Newborn screening	228
	Screening for medical intervention	230
	Screening for reproductive planning	230
	Screening to answer epidemiological questions	231
	Case-finding	232
	Problems created by false positive screening tests	232
	Screening technology	233
	Bacterial inhibition assays – the ‘Guthrie test’	233
	Tandem MSMS	235
	Radioimmunoassay	238
	Enzyme assay	238
	Specific mutation testing	239
	Suggested reading	239
9	Laboratory investigation	241
	Studies on the extent and severity of pathology	245
	Studies directed at the classification of disease processes (the ‘metabolic screen’)	245
	Investigation of ‘small molecule disease’	246
	Plasma ammonium	246
	Plasma lactate and pyruvate	246
	Plasma ketones and free fatty acids	246
	Amino acid analysis	247
	Neurotransmitters	253
	Organic acid analysis	254
	Acylcarnitines and acylglycines	256
	Porphyrins	260
	Approaches to the investigation of metabolic disorders	263

ix	Contents	
	Cellular metabolic screening studies	263
	Provocative testing	267
	Enzymology	270
	Molecular genetic studies	271
	Investigation of ‘organelle disease’	274
	Lysosomal disorders	274
	Disorders of mitochondrial energy metabolism	285
	Peroxisomal disorders	291
	Suggested reading	295
10	Treatment	297
	Control of accumulation of substrate	297
	Restricted dietary intake	297
	Control of endogenous production of substrate	301
	Acceleration of removal of substrate	303
	Replacement of product	306
	Reaction product replacement	306
	Gene product replacement	307
	Gene product stabilization	309
	Cofactor replacement therapy	309
	Mitochondrial electron transport defects	313
	Gene transfer therapy	314
	Organ transplantation	314
	Single gene transfer therapy	317
	Supportive measures	318
	Special considerations for adults with inherited metabolic diseases	318
	Suggested reading	321
	<i>Index</i>	324

Reviews of first edition

‘should be read thoroughly by any pediatric resident, genetic resident, or clinical fellow caring for patients with metabolic disorders’

American Journal of Medical Genetics

‘In short, this is an excellent guide to metabolic disease; it represents good value for money and, I suspect, will be more likely found in the owner’s pocket rather than on the shelf. It is recommended not only to the ‘busy physician’ and trainee, but to all those with an interest in metabolic disease.’

Journal of Inherited Metabolic Disease

‘The writing is lucid, direct and salted with personal observations. Clarke’s teaching skills shine forth from each page . . . It succeeds admirably, effectively demystifying the anxiety-provoking world of inherited biochemical illness.’

Canadian Medical Association Journal

‘J. T. R. Clarke has performed the amazing feat of distilling practical knowledge about the diagnosis of metabolic diseases into a small, yet ultimately pragmatic 280-page clinical guide . . . On the whole, I found this to be an amazing book which contains a vast amount of information presented in a concise, logical and well-organized fashion . . . I would recommend this book wholeheartedly to anyone involved in the diagnosis of inherited metabolic diseases.’

Journal of Genetic Counseling

Reviews of second edition

‘Dr Clarke’s enthusiasm and erudition are evident on every page of this book.’
Archives of Diseases of Childhood

‘An excellent book for physicians who find inherited metabolic diseases intimidating . . . The information is presented in such a clear and simple fashion that few people would find this book difficult to read . . . Clarke teaches a complex subject in a simple but complete manner.’
Canadian Medical Association Journal

‘This book’s strength lies in its simple straightforward clinical approach to this difficult area of medicine.’
Doctors.net.uk

‘If your clinical work brings you into contact with patients who may be hiding an inherited metabolic disease, Clarke’s *Guide* is clearly for you.’
Journal of the Royal Society of Medicine

‘To guide the reader in this assessment, a compact volume such as has been written by Dr Clarke is invaluable. Dr Clarke has succeeded in providing the reader with a user-friendly, inexpensive book that is up to date, and provides directions for further reading.’
European Journal of Paediatric Neurology

List of tables

1.1. Some examples of inborn errors of metabolism in which symptoms of disease are the result of substrate accumulation.	<i>page 5</i>
1.2. Some examples of inborn errors of metabolism in which symptoms of disease are the result of product deficiency.	8
1.3. Some examples of inborn errors of metabolism in which secondary metabolic defects play a prominent role in the production of symptoms of disease.	10
1.4. Some examples of inborn errors of metabolism occurring with high frequency among specific ethnic groups.	12
1.5. Some mechanisms of autosomal dominance.	13
1.6. IEM presenting in adulthood.	18
1.7. Some common non-metabolic conditions that are often confused with inherited metabolic diseases.	20
1.8. Disease websites.	22
1.9. Mutation websites.	24
2.1. Causes of pseudo-regression.	32
2.2. Initial investigation.	34
2.3. Seizures.	36
2.4. Classification of NCL.	40
2.5. Causes of acute metabolic encephalopathy to be considered at various ages.	54
2.6. Initial investigation of acute encephalopathy.	55
2.7. Differential diagnosis of inherited metabolic diseases presenting as acute encephalopathy.	55
2.8. Urinary organic acid abnormalities in the hereditary fatty acid oxidation defects.	64
2.9. Inherited metabolic diseases in which stroke may be a prominent feature.	65

xiii List of tables

2.10. Inherited metabolic diseases in which extrapyramidal movement disorders are prominent.	66
2.11. Protocol for the ischemic forearm exercise test.	75
2.12. Inherited metabolic diseases presenting as muscle cramping or myoglobinuria.	76
2.13. Differences between myophosphorylase deficiency and CPT II deficiency phenotypes.	77
2.14. Some common features of conditions caused by mitochondrial mutations.	79
2.15. Main clinical features of some relatively common mitochondrial syndromes.	80
2.16. Some mitochondrial syndromes caused by nDNA mutations.	81
2.17. Autonomic dysfunction	84
2.18. Some inherited metabolic diseases characterized by psychiatric or severe behavioral abnormalities.	85
3.1. Inherited metabolic diseases associated with renal tubular acidosis (RTA).	93
3.2. Clinical classification of lactic acidosis.	96
3.3. Urinary organic acids in multiple carboxylase deficiency.	100
3.4. Organic acidurias.	105
3.5. Flavoprotein dehydrogenases for which ETF/ETF dehydrogenase is the electron acceptor.	111
3.6. Some common causes of spurious or artefactual organic aciduria.	114
4.1. Causes of secondary carnitine deficiency.	124
4.2. Approach to hypoketotic hypoglycemia.	131
4.3. Relationship between metabolic defects and clinical manifestations of mitochondrial fatty acid β -oxidation defects.	133
4.4. Inherited metabolic diseases presenting as severe hepatocellular dysfunction organized according to age of onset.	134
4.5. Investigation of liver function.	139
5.1. Inherited metabolic diseases in which cardiomyopathy is prominent.	144
5.2. mtDNA point mutations associated with cardiomyopathy.	153
5.3. Some general clinical characteristics of cardiomyopathies	154
5.4. Plasma lipoproteins.	156
5.5. Familial hyperlipidemias.	158
6.1. Classification of inborn errors with significant dysmorphism.	164
6.2. Some clinical features of lysosomal disorders presenting as 'storage syndrome'.	171
6.3. Classification of peroxisomal disorders.	181
6.4. Conditions associated with chondrodysplasia punctata.	182

xiv List of tables

6.5. IEM of sterol biosynthesis.	187
6.6. Classification of subtypes of congenital disorders of glycosylation (CDG) syndrome.	188
6.7. Genetic and some acquired causes of homocystinuria.	193
6.8. Initial metabolic investigation of patients presenting with storage syndrome or dysmorphism.	195
7.1. Suspicion of an inherited metabolic disease.	199
7.2. Initial laboratory investigation of suspected inherited metabolic disease presenting in the newborn period.	201
7.3. Inherited metabolic disorders presenting in the newborn period with acute encephalopathy without metabolic acidosis.	203
7.4. Organic acidopathies presenting as acute illness in the newborn period.	211
7.5. Inherited metabolic diseases presenting with severe hepatocellular dysfunction in the newborn period.	218
7.6. Inherited metabolic diseases presenting as nonimmune fetal hydrops.	224
7.7. Initial management of possible inherited metabolic diseases presenting in the newborn period.	225
8.1. Classification of inherited disorders of phenylalanine metabolism.	234
8.2. Investigation of neonatal hyperphenylalaninemia.	235
8.3. Disorders detectable by tandem MSMS.	237
9.1. Clinical differentiation of organelle disease and small molecule disease.	243
9.2. Some general clinical characteristics of defects of organelle metabolism.	244
9.3. Chemical screening tests for amino acids and amino acid metabolites in urine.	249
9.4. Plasma amino acid abnormalities in various primary disorders of amino acid metabolism.	251
9.5. Primary disorders of amino acid transport.	253
9.6. Some common secondary abnormalities of plasma or urinary amino acids.	254
9.7. Neurotransmitter abnormalities	255
9.8. Biochemical abnormalities in the porphyrias.	260
9.9. Secondary porphyrias	263
9.10. Some common mutations causing specific inherited metabolic diseases.	272
9.11. Urinary MPS in the different mucopolysaccharidoses (MPS).	281
9.12. Summary of assays useful in the investigation of lysosomal storage diseases.	284
9.13. Subunits of mitochondrial electron transport chain.	290
9.14. Mitochondrial mutation analysis.	292
9.15. Some key functions of peroxisomes.	294
9.16. Laboratory abnormalities in some of the peroxisomal disorders.	294

xv	List of tables	
10.1.	Some examples of inborn errors of metabolism treatable by dietary manipulation.	299
10.2.	Various cofactors involved in intermediary metabolism and implicated in some cofactor-responsive inborn errors of metabolism.	310
10.3.	Treatment by organ transplantation.	315

List of figures

1.1. The primary consequences of inborn errors of metabolism.	<i>page</i> 4
1.2. The human mitochondrial genome.	15
1.3. The effect of heteroplasmy on the clinical expression of mtDNA mutations.	16
2.1. An approach to chronic encephalopathy.	33
2.2. MRI scans of the brain in patient with juvenile neuronal ceroid-lipofuscinosis.	38
2.3. Electron micrograph of conjunctival epithelium showing curvilinear and fingerprint inclusions in a patient with neuronal ceroid-lipofuscinosis.	39
2.4. Axial MRI scan and MRS of brain of a patient with Leigh disease.	42
2.5. Coronal MRI scan of the brain of a child with Leigh disease.	43
2.6. Axial MRI scan of the brain of a child with MELAS.	44
2.7. Axial CT scan of the brain of an infant with Tay-Sachs disease.	46
2.8. CT scan of the brain of an infant with Canavan disease.	47
2.9. CT and MRI scans of the brain in X-linked adrenoleukodystrophy.	49
2.10. MRI scan of the brain in late-onset GM2 gangliosidosis.	50
2.11. Summary of the major causes of acute encephalopathy.	54
2.12. Summary of normal ammonium metabolism.	57
2.13. An approach to the diagnosis of hyperammonemia in older children.	58
2.14. MRI in GAI.	70
2.15. Photomicrograph of skeletal muscle stained by the modified Gomori trichrome method showing ragged-red fibers.	83
3.1. Approach to the investigation of metabolic acidosis.	95
3.2. Metabolic sources and fates of pyruvate.	97
3.3. Summary of ketone metabolism.	102
3.4. Branched-chain amino acid metabolism.	103
3.5. Relationship between cobalamin, methylmalonic acid (MMA), and homocysteine metabolism.	108

xvii **List of figures**

4.1. Overview of key reactions in gluconeogenesis.	121
4.2. The Cori cycle.	123
4.3. Approach to the differential diagnosis of hypoglycemia.	126
4.4. Electron micrograph of normal liver (a) and liver in glycogen storage disease (b).	128
4.5. Overview of fatty acid metabolism.	132
4.6. Electron micrograph of liver in Wilson disease.	138
5.1. Investigation of metabolic cardiomyopathy.	148
5.2. Radiograph of the chest in an infant with Pompe disease (GSD II).	150
5.3. ECG of infant with Pompe disease (GSD II).	150
5.4. Typical angiokeratomata on the penis of a man with Fabry disease.	152
5.5. Tuberous xanthomas on the hands of a seven-year-old boy with familial hypercholesterolemia.	157
6.1. Facial features of patients with various lysosomal storage disorders.	166
6.2. Radiographs of patient with Hurler disease (MPS IH).	169
6.3. Alder-Reilly bodies in peripheral blood lymphocyte from patient with Hurler disease (MPS IH).	170
6.4. Radiograph and MRI scan of the lower extremities in Gaucher disease.	175
6.5. Typical storage macrophage in the bone marrow of a patient with Gaucher disease.	176
6.6. Facial features of a newborn infant with classical Zellweger syndrome.	178
6.7. Radiograph of the knee in a patient with Zellweger syndrome showing stippling of the patella.	179
6.8. MRI scan of the brain in patient with Zellweger syndrome.	180
6.9. Facial features of an infant with Menkes disease.	184
6.10. Facial features of an infant with mevalonic aciduria.	185
6.11. Smith-Lemli-Opitz syndrome.	186
6.12. Lipodystrophy of the buttocks and thighs of a 6-week-old infant with congenital disorder of glycosylation syndrome.	190
6.13. Isoelectric focusing of plasma transferrin in CDG syndrome.	192
6.14. Metabolism of homocysteine and methionine.	193
7.1. Imaging of the brain of an infant with maple syrup urine disease.	204
7.2. Differential diagnosis of urea cycle enzyme defects in the newborn.	206
9.1. Some typical pathological urinary organic acid patterns.	257
9.2. Heme biosynthesis and the porphyrias.	262
9.3. Schematic diagram showing principles of complementation analysis.	265
9.4. Principles of cybrid analysis.	267
9.5. Blue native polyacrylamide gel electrophoresis (BN-PAGE) analysis.	268
9.6. Electron micrograph of conjunctival biopsy in mucopolipidosis type IV.	276

xviii List of figures

9.7. Electron micrographs of skin biopsies in some lysosomal storage diseases.	277
9.8. Summary of glycoprotein degradation.	282
9.9. Thin-layer chromatographic analysis of urinary oligosaccharides.	283
9.10. Overview of mitochondrial fatty acid metabolism.	287
9.11. Mitochondrial fatty acid oxidation.	288
9.12. Complexes of the mitochondrial electron transport chain.	289
10.1. Effects of NTBC (2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexane-dione) on tyrosine metabolism.	303

Preface

In this enlarged third edition of *A Clinical Guide to Inherited Metabolic Diseases*, I have preserved the basic, clinical approach first developed in the first edition of the book. However, advances in many fields over the past 5 years have made it necessary to add significantly in some areas, such as mitochondrial disorders and the congenital disorders of glycosylation. The challenge continues to be to find ways to translate discoveries made in research laboratories, which understandably focus on biochemical and genetic principles, into a clinically relevant format organized in a way to facilitate the early recognition of the disorders by clinicians. For example, inherited defects in mitochondrial electron transport (ETC) may present as neurological syndromes (encephalopathy, myopathy, movement disorder), cardiac syndrome (cardiomyopathy), hepatic syndrome, metabolic acidosis, or catastrophic illness in the newborn. The challenge has been to develop and present a clinical approach to mitochondrial ETC defects without being unnecessarily repetitious. The chapter on ‘Laboratory investigation’ is important in this respect because it provides an approach to the transition in thinking between the recognition of various clinical signs and the biochemical and genetic investigation of possible causes of disease. By the very nature of laboratory investigation, it is also organized biochemically, which draws together the consideration of all those disorders presented in various different chapters as clinical problems. The book should, therefore, be viewed as a series of clinical chapters, which overlap in terms of biochemical and genetic organization and content in the chapter on ‘Laboratory investigation’. It follows that reference to any topic presented in a clinical chapter ought to be considered also in the light of the appropriate section on the chapter on ‘Laboratory investigation’ – they go together.

I have added significantly to the chapter, ‘Neurologic syndrome’, as new mechanisms of disease are discovered, such as inherited disorders of neurotransmitter metabolism and the channelopathies. The chapter on ‘Newborn screening’ has also been expanded as this field grows, along with experience with the application of tandem mass spectrometry as a screening technology. The chapters on ‘Laboratory

xx **Preface**

investigation’ and ‘Treatment’ have had to be modified significantly in the light of new technological developments in these areas. I have also added to and updated the bibliographies at the end of each chapter, though the number of publications cited is still a tiny fraction of the literature on the subjects discussed. In many cases, I have sacrificed some outstanding articles focusing on advances in basic research for articles I thought would be more relevant to clinicians dealing daily with patient problems.

For intellectual support and stimulation during the preparation of this edition of *A Clinical Guide*, I am again grateful to my colleagues, Annette Feigenbaum, Susan Blaser, Bill Hanley, Brian Robinson, John Callahan, and Eve Roberts, and to the people who slave away in the diagnostic labs, all at the Hospital for Sick Children. In addition, however, I owe a great deal to colleagues in other centers, scattered throughout the world, who read the second edition and suggested some changes which I am convinced will make this edition even better. I owe Charles Scriver special thanks for comments on the last edition of this book which have resulted in some important additions to the current edition. As usual, I am indebted to the large number of residents and fellows who rotated through the genetic metabolic service at the Hospital, stimulating me to think clearly about the clinical problems we tackled together. Gustavo Maegawa, from Brazil, Nouriya Al-Sannaa, now in Dhahran, Saudi Arabia, Aneal Khan, now at McMaster University in Hamilton, Pranesh Chakraborty, who is now at the Children’s Hospital of Eastern Ontario, Nicola Poplawski, at the Adelaide Women’s and Children’s Hospital in Adelaide, and Julian Raiman, now at Guy’s Hospital in London, merit special mention in this regard.

Many colleagues provided material for the figures in the book: Jim Phillips provided the electron micrographs of the liver, and Venita Jay supplied the electron micrographs of conjunctival epithelium and the photomicrograph of muscle. The photographs of patients with carbohydrate-deficient glycoprotein syndrome (now called congenital disorders of glycosylation) and mevalonic aciduria were provided by Jaak Jaiken and Georg Hoffmann, respectively. Jaak Jaiken also supplied the photograph of the isoelectric focusing of plasma transferrin shown in Chapter 6. Joe Alroy kindly provided the original electron micrographs showing the changes in skin in patients with lysosomal disorders appearing in Chapter 9. Margaret Nowaczyk and Chitra Prasad provided photographs of patients with Smith-Lemli-Opitz syndrome (Chapter 6), and Eric Shoubbridge provided the photograph of the blue native PAGE in Chapter 9. I am again particularly grateful to Susan Blaser for the neuroimaging studies reproduced in Chapter 2 on ‘Neurologic syndrome’.

Peter Silver, at Cambridge University Press, continued to provide moral and technical support during the preparation of the book. And once again, my wife, Cathy, encouraged and supported me throughout the project, often at great personal cost.